Schwab US Large Cap Growth ETF vs Teladoc Health Inc — how do they compare? Schwab US Large Cap Growth ETF trades at $36.63 (market cap $65.01B), while Teladoc Health Inc trades at $5.6 (market cap $1.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 64.4× Teladoc Health Inc's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and Teladoc Health Inc for 39 Days on average.
| SCHG | TDOC | |
|---|---|---|
Market Cap | $65.01B | $1.01B |
Volume | 8,554,399 | 4,668,477 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $9.72 |
52-Week Low | $28.10 | $4.47 |
Typical Hold Time | 50 Days | 39 Days |
Enterprise Value | — | $1.27B |
Signals from Pluang's Aura AI — not financial advice
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.
The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →